Skip to content

Amber Therapeutics raises £80m for urinary incontinence treatment

Amber Therapeutics
Image credit: Gorodenkoff / Shutterstock

London-based medical technology startup Amber Therapeutics has closed a $100m (£78m) Series A funding round.

Founded in 2021, Amber Therapeutics is developing adaptive neuromodulation therapy to treat mixed urinary incontinence (MUI).

The company said its flagship treatment, Amber-UI, is the first fully implantable adaptive neuromodulation therapy in clinical development for MUI.

Amber-UI works by targeting the pudendal nerve through minor invasive surgery.

“Securing this significant financing round from such a blue-chip group of US and UK investors is a huge validation of our therapy value proposition and the quality of the team we have built,” said Aidan Crawley, CEO of Amber Therapeutics.

Amber Therapeutics has begun planning for pilot studies in Europe and the US.

“Amber can now execute the critical next phase of our strategy to take Amber-UI to US regulatory approval and fulfil our mission of making this breakthrough therapy available to the millions of women suffering from mixed urinary incontinence,” Crawley added.

The funding round was led by New Enterprise Associates as part of an investment syndicate featuring F-Prime Capital, Lightstone Ventures, and Intuitive Ventures, alongside existing investors Oxford Science Enterprises and 8VC.

“We believe Amber Therapeutics has the potential to become the first-ever approved therapy for a significantly under-addressed patient population,” said Tiffany Le, Principal at New Enterprise Associates.

“This technology is the culmination of decades of research, and we are proud to support such an innovative therapy that could provide an effective treatment for an often overlooked and under-discussed condition that affects so many women worldwide.”

Topics

Register for Free

Get daily updates and enjoy an ad-reduced experience.

Already have an account? Log in